Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 10/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6132192 | 0.96 | PTGS2 (0.63) | PTGS2PTGS1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6132484 | 0.96 | PTGS2 (0.63) | PTGS2PTGS1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6681240 | 0.93 | PTGS2 (0.60) | PTGS2PTGS1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5865649 | 0.93 | PTGS2 (0.60) | PTGS2PTGS1L3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL6132399 | 0.91 | PTGS2 (0.58) | PTGS2PTGS1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6885231 | 0.91 | PTGS2 (0.58) | PTGS2PTGS1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5204715 | 0.91 | PTGS2 (0.58) | PTGS2PTGS1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL28806023 | 0.90 | PTGS2 (0.60) | PTGS2PTGS1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6132400 | 0.90 | PTGS2 (0.57) | PTGS2PTGS1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL27905338 | 0.90 | PTGS2 (0.60) | PTGS2PTGS1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191155-A1 | Triazole derivatives | ASTELLAS PHARMA INC. (JP) | 2003-10-09 | — | — | US | claimed |
| US-20130137739-A1 | SOLID DISPERSION COMPRISING TRIAZOLE COMPOUND | ASTELLAS PHARMA, INC. | 2013-05-30 | — | — | US | disclosed |
| EP-2581084-A1 | SOLID DISPERSION COMPRISING TRIAZOLE COMPOUND | Astellas Pharma Inc. (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-6927230-B2 | Triazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-09 | — | — | US | disclosed |
| US-20030191155-A1 | Triazole derivatives | ASTELLAS PHARMA INC. (JP) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191155-A1 | Triazole derivatives | CBR1, CBR3, CYP1B1 | PTGS2 2680/4885PTGS1 1504/4885CYP1A2 30/4885 |
| US-20130137739-A1 | SOLID DISPERSION COMPRISING TRIAZOLE COMPOUND | CYP3A4, CYP3A43, CYP3A7 | PTGS2 3116/4885PTGS1 2201/4885CYP1A2 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.